GALE Share Price

Open 0.39 Change Price %
High 0.39 1 Day 0.00 0.00
Low 0.38 1 Week -0.01 -2.50
Close 0.39 1 Month 0.04 11.43
Volume 244136 1 Year 0.12 44.44
52 Week High 4.75
52 Week Low 0.16
GALE Important Levels
Resistance 2 0.40
Resistance 1 0.40
Pivot 0.39
Support 1 0.38
Support 2 0.38
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
OPTT 2.00 38.89%
SPPI 19.67 36.03%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.06 20.00%
CREE 34.16 16.43%
AMPE 1.15 16.16%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Galena Biopharma, Inc. (NASDAQ: GALE)

GALE Technical Analysis 2
As on 18th Oct 2017 GALE Share Price closed @ 0.39 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.96 & Buy for SHORT-TERM with Stoploss of 0.38 we also expect STOCK to react on Following IMPORTANT LEVELS.
GALE Target for October
1st Target up-side 0.41
2nd Target up-side 0.45
3rd Target up-side 0.49
1st Target down-side 0.29
2nd Target down-side 0.25
3rd Target down-side 0.21
GALE Other Details
Segment EQ
Market Capital 139060160.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.galenabiopharma.com
GALE Address
GALE
4640 SW Macadam Avenue
Suite 270
Portland, OR 97239
United States
Phone: 855-855-4253
GALE Latest News
Interactive Technical Analysis Chart Galena Biopharma, Inc. ( GALE NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Galena Biopharma, Inc.
GALE Business Profile
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.